Drug intelligence / Profile preview

NES Pharma

Development stage: Preclinical
Lead developer: BIO-XL
Modality: Small Molecules
Administration: Oral

Overview

NES Pharma is a multimodal, orally delivered small molecule being developed by BIO-XL for the treatment and prevention of dementia. It specifically targets glutamate-driven neurotoxicity at the Mild Cognitive Impairment (MCI) stage. The drug is designed to mitigate the neurodegenerative effects associated with glutamate imbalance, aiming to preserve cognitive function in early-stage patients. It is currently in preclinical development.

Other names: BIO-XL-glutamate

Targets

Glu (Glutamate)

Beyond the preview

Go deeper on NES Pharma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NES Pharma.

Explore the full profile